Clinitech Laboratory Limited IPO

Apply 0
Avoid 0

They operate a network of 8 diagnostic centers located in and around Thane and Navi Mumbai, providing a wide range of diagnostic and healthcare tests and services.

Their promoters bring over 30 years of experience in the diagnostic industry, ensuring high standards and expertise in our operations.

Their NABL (National Accreditation Board for Testing and Calibration Laboratories) accredited labs are equipped with modern technology and high-end equipment, allowing them to conduct more than 300,000 tests annually.

They offer over 150 different tests, categorized under the following heads:
i. Biochemistry tests
ii. Immunology tests
iii. Hematology tests
iv. Molecular Biology tests
v. Serology tests
vi. Microbiology tests
vii. Histopathology tests

Their commitment to quality and advanced diagnostic solutions positions them as a trusted provider in the healthcare industry.

Objects of the Clinitech Laboratory Limited IPO:

The Company proposes to utilise the Net Proceeds from the Fresh Issue towards funding the following objects: i. Expansion of Diagnostic Centres; ii. General Corporate Purposes

Clinitech Laboratory Limited IPO Details:

Open Date: Jul 25 2024
Close Date: Jul 29 2024
Total Shares: 602,400
Face Value: ₹ 10 Per Equity Share
Issue Size: 5.78 Cr.
Lot Size: 1200 Shares
Issue Price: ₹ 96 Per Equity Share
Listing At: BSE SME
Listing Date: Aug 01 2024

Promoters And Management:

Jagdish Umakant Nayak, 57, the founding promoter and director since the company's inception, was redesignated as Chairman and Managing Director on September 30, 2023. A graduate in microbiology from the University of Bombay (1987) with a Diploma in Medical Laboratory Technology from Somaiya Vidyavihar (1989), he has over 30 years of experience in diagnostic healthcare. At Clinitech, he formulates business growth strategies, maintains customer relationships, markets products and services, oversees daily operations, and leads new product development to address customer health issues. Jyoti Jagdish Nayak, 53, the founding promoter and director since the company's inception, was redesignated as Whole Time Director on September 30, 2023. She graduated in microbiology from the University of Bombay (1991), earned a Post Graduate Diploma in Medical Laboratory Technology from the Board of Technical Education, Maharashtra State (1993), and completed a master's in microbiology from Apex Professional University, Arunachal Pradesh (2018). With over 30 years of experience in diagnostic healthcare, she manages diagnostic centers and oversees the day-to-day operations at Clinitech. Ashutosh Jagdish Nayak, aged 26 years is the director on the board of the Company since 2022 and is redesignated as Non-Executive Director w.e.f. September 30, 2023. He is a MBBS Bachelor of Medicine, Bachelor of Surgery from Maharashtra University of Health Sciences. He has around 2 years of experience with multi specialty hospitals in the field of patient treatment. At Clinitech, he is currently responsible as Public Relationship Officer explaining reports etc. to patients.

Financials of Clinitech Laboratory Limited IPO:

Particular (In lakh) Mar-24 Mar-23 Mar-22
Revenue from Operations 640 635 638
Cost of Material Consumed 110 117 145
Laboratory testing charges 23 22 35
Employee Cost 229 203 178
Other Expenses 180 157 174
EBITDA 98 136 106
EBIDTA Margin 15.31% 21.42% 16.61%
Other income 3 1 7
Depreciation 44 44 38
Interest 7 6 6
Profit before tax 50 86 69
Tax 13 25 19
Net profit 37 61 51
NPM (%) 5.75% 9.59% 7.91%
EPS 1.62 2.67 2.23

Comparison With Peers:

Name of the Companies Revenue (Cr) Profit (Cr) EPS P/E CMP Mcap
Clinitech Laboratory Limited 6.4 0.37 1.62 59 96 21.9
Dr Lal Pathlabs Ltd. 2227 362 42.85 71 3042 25394
Thyrocare Technologies Ltd. 524 98 13.43 50 476 3952
Krsnaa Diagnostics Ltd. 590 59 18.14 37.5 680 2197
*All the data is as per FY24

Recommendation on Clinitech Laboratory Limited IPO:

Review and Recommendation of Clinitech Laboratory by team IZ is 3/10. 1. Clinitech Laboratory Limited is a premier provider of diagnostic and healthcare tests and services, operating through a network of eight diagnostic centers located in and around Thane and Navi Mumbai. Their extensive experience and commitment to quality have established us as a trusted name in the industry. 2. Extensive Testing Capabilities They conduct over 300,000 tests annually in their state-of-the-art labs, which are accredited by the National Accreditation Board for Testing and Calibration Laboratories (NABL). Their labs are equipped with the latest technology and high-end equipment, enabling them to provide accurate and timely results to their clients. 3. Range of Services Their diagnostic centers offer a wide array of over 150 tests, categorized under various specialized areas: i. Biochemistry Tests                       ii. Immunology Tests                  iii. Hematology Tests iv. Molecular Biology Tests             v. Serology Tests                         vi. Microbiology Tests vii. Histopathology Tests 4. Competition They operate in a highly competitive market where the primary factors of competition include the quality of service, timely delivery, and pricing. 5. The Revenue has Increased from Rs.6.3 Crores in FY22 to Rs.6.4 Crores in FY24. 6. The EBITDA has Decreased from 1 Crores in FY22 to 98 Lakhs in FY24. 7. The PAT has Decreased from 51 Lakhs in FY22 to 37 Lakhs in FY24. 8. As per FY24, CFO/EBITDA is 1.07, and EPS is 1.62, 9. Market Capitalization is 22 Crores and P/E is 59.02x based on FY24.

Lead Manager of Clinitech Laboratory Limited IPO:

  1. First Overseas Capital Limited

Registrar of Clinitech Laboratory Limited IPO:

  1. Bigshare Services Private Limited

Company Address:

Clinitech Laboratory Limited AL-1/545, Sector 16, Airoli Opposite Radhikabai Meghe Vidyalaya Navi Mumbai, Thane - 400708, Phone: +91 22 27792281 Email: ipo@clinitechlab.com Website: https://clinitechlab.com/

Discussion on Clinitech Laboratory Limited IPO:

Leave a Reply